Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Omacetaxine mepesuccinate (Synribo) demonstrated a major molecular response (MMR) rate of 19.2% and a complete cytogenetic response (CCyR) rate of 16.1% at 6 months in adult patients with chronic phase-chronic myeloid leukemia (CP-CML) who have received ≥ 2 prior TKIs (ATP-competitive tyrosine kinase inhibitors).
• Ponatinib exhibited an MMR rate ranging from 19.0% to 66.7% and a CCyR rate from 21.4% to 64.8% at 6 months, while asciminib showed an MMR rate of 23.3% to 25.5% and a CCyR rate of 38.7% to 40.8% at the same time point. Bosutinib had an MMR rate of 13.2% and CCyR rates between 18% and 24.2% at 6 months.
• The studies indicate that the findings focus on patients resistant or intolerant to multiple lines of TKI therapy, underscoring the need for additional treatment strategies in this subgroup.
• There is no safety information available in the reviewed studies.
• The Population Types and Subgroup Considerations section highlights that the focus is on adult patients with chronic phase-chronic myeloid leukemia (CP-CML) who have received ≥ 2 prior TKIs, specifically addressing those who are resistant or intolerant to multiple lines of TKI therapy, indicating a subgroup that may particularly benefit from novel treatment options, including omacetaxine.